FDA ap­proves Tris Phar­ma's non-stim­u­lant pe­di­atric AD­HD liq­uid med­ica­tion

The FDA ap­proved Tris Phar­ma’s Ony­da XR to treat AD­HD in chil­dren who are at least 6 years old.

It’s the first liq­uid non-stim­u­lant AD­HD …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.